We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Standard BioTools Inc (LAB) USD0.001

Sell:$1.59 Buy:$1.60 Change: $0.01 (0.62%)
Market closed |  Prices as at close on 30 June 2022 | Switch to live prices |
Change: $0.01 (0.62%)
Market closed |  Prices as at close on 30 June 2022 | Switch to live prices |
Change: $0.01 (0.62%)
Market closed |  Prices as at close on 30 June 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Standard BioTools Inc. is focused on unleashing tools to accelerate breakthroughs in human health. The Company has a portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines. It provides reliable and repeatable insights into health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on translational and clinical research, including oncology, immunology, and immunotherapy. The Company offers instruments, such as Access Array, AccuLift, Biomark HD, Biomark X, C1, CyTOF XT, Flow Conductor, Helios a CyTOF System, Hyperion Imaging System, Hyperion+ Imaging System, and Juno. It distributes its systems through its direct sales force and support organizations.

Contact details

2 Tower Place, Suite 2000
United States
+1 (650) 2666000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$135.19 million
Shares in issue:
77.25 million
Life Sciences Tools & Services
United States
US dollar

Key personnel

  • Michael Egholm
    President, Chief Executive Officer, Director
  • Vikram Jog
    Chief Financial Officer
  • Alex Kim
    Chief Operating Officer, Senior Vice President - Corporate Development and Investor Relations
  • Angela Peters
    Chief Human Resource Officer
  • Nicholas Khadder
    Senior Vice President, General Counsel, Corporate Secretary
  • Bradley Kreger
    Senior Vice President - Global Operations
  • Emi Zychlinsky
    Senior Vice President - Regulatory Affairs & Quality Assurance
  • Jeremy Davis
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.